Sanofi Genzyme
500 Kendall Street
Cambridge
Massachusetts
02142
United States
Tel: 617-252-7500
Fax: 617-252-7600
Website: https://www.sanofigenzyme.com/
About Sanofi Genzyme
About Genzyme
Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before.
Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
776 articles with Sanofi Genzyme
-
Biogen successfully fended off a patent challenge from generic company Mylan over its multiple sclerosis (MS) drug Tecfidera.
-
As the J.P. Morgan Healthcare Conference winds down for 2020, one of the big topics was the general lack of big deals. Still, there were some general trends and for today, some news.
-
With the 2020 elections looming though, and lawmakers across the country drafting legislation aimed at curbing price increases, some companies are carefully examining the landscape as they approach pricing.
-
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
-
As is often the case at the beginning and end of the year, a number of companies announced layoffs. Other news is related to lawsuits and an overall positive story about cancer death rates. Here’s a look.
-
The trials met the primary endpoints, with ofatumumab demonstrating a highly significant and clinically meaningful decrease in the number of confirmed relapses. The trials also hit key secondary endpoints, delaying the time to confirmed disability progression.
-
“Our alliance with Sanofi Genzyme has been foundational for Voyager as we optimized the development of capsids, transgenes and gene therapy delivery,” stated Andre Turenne, president and chief executive officer of Voyager. “We look forward to this new stage of the relationship and to advancing ou...
-
Senate President, Speaker of the House, Leaders of Legislation, Medicine and Advocacy Join Forces to Lead the Nation in Recognizing Prostate Cancer as a Public Health Priority and Leading Disparity
4/25/2019
AdMeTech Foundation's 11th Annual Prostate Cancer Awareness Day at the State House Highlights Massachusetts Model of National Leadership in Public Awareness, Education and Research
-
Health Canada issues Notice of Compliance with Conditions (NOC/c) for LibtayoTM (cemiplimab), the first and only biologic for the treatment of advanced cutaneous squamous cell carcinoma (CSCC)
4/11/2019
Sanofi Genzyme announced that Health Canada has issued a Notice of Compliance with conditions for LibtayoTM for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
-
With Boston and the surrounding area being one of the centers of the pharmaceutical world, it should come as no surprise that some of the top-selling medications are based in the Bay State.
-
BioSpace Movers and Shakers Nov. 12
11/12/2018
Biopharma companies name new members of their leadership teams. Who made big moves this week? -
Gail Maderis, currently president and chief executive officer of South San Francisco-based Antiva Biosciences, has a rock-solid resume.
-
BioSpace Movers and Shakers Nov. 5
11/5/2018
Biopharma companies make key appointments to fill leadership positions. Let's take a look! -
Shining a Light on Diagnosis for Rare Genetic Disease Patients
10/15/2018
Patients with rare genetic diseases can face a difficult path to a proper diagnosis. Because there is a lower awareness of these diseases and they have symptoms which may initially be confused with more common diseases, diagnosis can take several years with patients often consulting with multiple physicians.
-
Sanofi presents new data on Aubagio® (teriflunomide)
10/10/2018
New data suggest slowing of whole brain volume loss with Aubagio is associated with delayed conversion to clinically definite multiple sclerosis
-
Cambridge, Mass.-based Editas Medicine, one of the leading CRISPR gene editing companies, is losing its chief medical officer. Gerald Cox will step down from his role at the end of the year.
-
Branded Direct-to-Consumer Advertising Likely to Provide a Bump in Patient Requests for Sanofi/Regeneron's Dupixent, but Insurance Coverage and Out-of-Pocket Costs Continue to be Key Barriers for the Only Approved Atopic Dermatitis Biologic
8/15/2018
According to the latest update from Spherix Global Insights, while dermatologists continue to report high satisfaction with the first FDA approved biologic, there is still a large unmet need for new pharmacologic treatments for atopic dermatitis.
-
Sigilon Taps Bioverativ Veteran as New CEO After Paul Wotton Steps Aside Due To Family Matters
8/14/2018
A little more than one year after Flagship Pioneering launched Sigilon Therapeutics, the company has a new chief executive officer. This morning Sigilon announced Bioverativ veteran Rogerio Vivaldi will helm the Cambridge, Mass.-based company. -
Regeneron Pharmaceuticals reported its second-quarter financial results, citing quarterly total revenues of $1.608 billion, up 9 percent from the same quarter in 2017 of $1.470 billion.
-
Fearing disruption of drug inventories when Brexit takes place, Sanofi, AstraZeneca and Novartis have indicated they are stockpiling drugs.